1,721,004 research outputs found
sj-pdf-1-jbm-10.1177_03936155221088886 - Supplemental material for Evaluation of HSP-27, BAP1, BRAF V600E, CCR7, and PD-L1 expression in uveal melanoma on enucleated eyes and metastatic liver tumors
Supplemental material, sj-pdf-1-jbm-10.1177_03936155221088886 for Evaluation of HSP-27, BAP1, BRAF V600E, CCR7, and PD-L1 expression in uveal melanoma on enucleated eyes and metastatic liver tumors by Abdullah Ağın, Hayyam Kiratli, Servet Guresci, Berrin Babaoglu, Jale Karakaya and Figen Soylemezoglu in The International Journal of Biological Markers</p
Astrocytic Tumors
Retinal astrocytic tumors are benign neoplasms that may present in three major clinical forms, namely, retinal astrocytic hamartomas, acquired retinal astrocytomas and reactive retinal astrocytic tumors. Astrocytic hamartomas typically occur in patients with tuberous sclerosis complex. These tumors may be solitary or multiple, appear creamy-white in color and may contain calcified areas. Histopathologically, they are composed of elongated fibrous astrocytes. Most tumors are stable throughout life and do not require treatment. Acquired retinal astrocytomas are not associated with tuberous sclerosis complex and can be seen at any age. They are usually solitary and yellow-white in color and show progression that results in exudative retinal detachment. Management includes photodynamic therapy, but most eyes end up with enucleation. Reactive retinal astrocytic tumors, also known as retinal vasoproliferative tumors, are pink-yellow lesions typically developing in the inferotemporal quadrant of the peripheral fundus and are often associated with large amounts of exudation and visual loss. This tumor may be secondary to retinitis pigmentosa, Coats disease, pars planitis or trauma. Treatment options include cryotherapy, plaque brachytherapy, photodynamic therapy and intravitreal anti-vascular endothelial growth factor injections. Malignant transformation or systemic metastasis has not been reported for any of the retinal astrocytic tumors. (C) 2016 S. Karger AG, Base
- …
